✖


Jump to content

Schott Pharma

Edit links
Schott Pharma AG & Co. KGaA
Company typeKGaA with Aktiengesellschaft as partner with unlimited liability
FWB: 1SXP
ISINDE000A3ENQ51
IndustryHealthcare
FoundedAugust 1, 2022; 2 years ago (2022-08-01)
HeadquartersMainz, Germany
Key people
Andreas Reisse, CEO
Almuth Steinkühler, CFO
ProductsPharmaceutical drug containment and delivery systems
Revenue€899 million (2022/2023)[1]
OwnerSchott AG
Number of employees
4,646 (as of September 30, 2023)[1]
Divisions
  • Drug Containment Solutions
  • Drug Delivery Systems
Websiteschott-pharma.com

Schott Pharma (stylized as SCHOTT Pharma) is a provider of drug containment solutions and delivery systems for injectable drugs.[2][3] Headquartered in Mainz, Germany,[4][5] the company operates in 14 countries.[6]

History

[edit]
Filling Schott glass ampoules with medications (1932)
Schott & Gen. advertisement for borosilicate glass vials (1923)

In 1887, Otto Schott developed borosilicate glass, a form of glassware used to reagent bottles and flasks. From 1911, Schott manufactured borosilicate glass tubing for the production of pharmaceutical ampoules and vials.[7]

Schott Pharma was established as a standalone company in 2022 under the name Schott Pharma AG & Co. KGaA[8][5] through an equity carve-out (or spin-off) from Schott AG, a manufacturer of specialty glass and glass-ceramics.[9][10]

In the same year, the company announced their plans to present an IPO, but this was reportedly postponed to 2023 due to the Ukraine war.[4] In September 2023, Schott Pharma went public on the Frankfurt Stock Exchange. The IPO was initially priced at 27€ per share,[11][12] and a potential valuation of up to 4.1 billion euros,[13] but increased the share price to 30€ the following day.[14] The IPO was the largest of the year in Germany.[15][16] In December 2023, Schott Pharma was included in the SDAX.[17]

Production & Manufacturing

[edit]

The company is headquartered in Mainz and operates in 16 locations across 14 countries.[18]

Europe

[edit]

North America

[edit]

South America

[edit]

Asia

[edit]

Products

[edit]

Schott Pharma develops and manufactures drug containment solutions and delivery systems for injectable drugs, which it supplies to companies in the biotechnology and pharmaceutical industries.[23]

Its business is divided into two divisions:

  • Drug Containment Solutions: pharmaceutical vials, cartridges, and glass ampoules[24]
  • Drug Delivery Systems: prefillable glass syringes and syringes made from Cyclic olefin copolymers (COC), suitable for deep-cold medications.[25]
  • Prefillable glass syringe
    Prefillable glass syringe
  • Prefillable polymer syringe
    Prefillable polymer syringe
  • Ampoule
    Ampoule
  • Vial
    Vial
  • Cartridge
    Cartridge

Governance

[edit]

Schott Pharma is a subsidiary of SCHOTT AG, who has controlling shares of 77%(as of 2023: 77%).[16][14] SCHOTT AG is owned by the Carl Zeiss Foundation.[21]

Schott Pharma was listed on the Frankfurt Stock Exchange's SDAX in 2023.

Parent Company Board of Directors

[edit]
  • Frank Heinricht (CEO of Schott AG) [19]
  • Almuth Steinkühler (Chief Financial Officer of Schott AG)[26]

Independent Supervisory Board

[edit]

In 2023 SCHOTT AG appointed a Supervisory Board for the subsidiary Schott Parma AG as follows:[27][28]

  • Peter Goldschmidt, (Chairman)
  • Dr. Wolfgang Wienand (Chairman of the Executive Board of Siegfried Holding AG)
  • Eva Kienle (CFO of KWS Saat SE & Co. KGaA)
  • Ann-Kristin Erkens (Corporate Senior Vice President, Financial and Business Controlling at Henkel Adhesive Technologies)
  • Christine Wening (employee stakeholder)
  • Mario Just (employee stakeholder)

Financial Results

[edit]
2022/23 2023/24
Turnover
Net Profit

References

[edit]
  1. ^ Jump up to: a b SCHOTT Pharma Annual Report 2022/2023 (accessed February 08, 2024)
  2. ^ Kansteiner, Fraiser (2023-12-23). "Glass specialist Schott Pharma touts 2023 sales growth, Serbia expansion and hiring plans". Fierce Pharma. Retrieved 2024-04-08.
  3. ^ "EQS-News: SCHOTT Pharma bestätigt Prognose für das Geschäftsjahr 2024 anlässlich seiner Q2-Ergebnisse; Geschäftsjahr 2025 durch geringeres Wachstum bei Spritzen beeinflusst" [EQS-News: SCHOTT Pharma confirms forecast for the 2024 financial year on the occasion of its Q2 results; financial year 2025 influenced by lower growth in syringes]. 4Investors.de (in German). 2024-05-14. Retrieved 2024-06-24.
  4. ^ Jump up to: a b Ibrahim, Samir (2023-09-28). "Schott Pharma startet erfolgreich an der Frankfurter Börse". tagesschau.de (in German). Retrieved 2024-06-24.
  5. ^ Jump up to: a b c Nünchert, Ike (2022-08-03). "SCHOTT Pharma: Carve-Out für ein mögliches IPO" [SCHOTT Pharma: Carve-Out for a possible IPO]. Going Public. Retrieved 2024-06-24.
  6. ^ "Größter Börsengang in 2023: So hat sich die SCHOTT Pharma-Aktie seit ihrem IPO entwickelt - und so könnte es in 2024 nun weitergehen". finanzen.net. 2024-01-24. Retrieved 2024-02-28.
  7. ^ "Impfstoff-Ampullen – Rohrglas für Lebensretter - VBG Spezial". glaskeramik.org. VBG. 2021-07-04. Retrieved 2024-02-28.
  8. ^ Dunleavy, Kevin (2023-09-06). "After one year as standalone business, glassmaker Schott Pharma sets course for IPO". Fierce Pharma. Retrieved 2024-06-24.
  9. ^ Kansteiner, Fraiser (2022-01-08). "Glass maker Schott's pharma business sets out on its own. Will an IPO follow?". Fierce Pharma. Retrieved 2024-02-28.
  10. ^ Landsteiner, Fraiser (2022-08-01). "Glass maker Schott's pharma business sets out on its own. Will an IPO follow?". Fierce Pharma. Retrieved 2024-06-24.
  11. ^ Gopinath, Swetha (2023-09-28). "Germany's Schott Raises €813 Million in IPO of Medical-Glass Arm". www.bloomberg.com. Retrieved 2024-06-24.
  12. ^ gsp (2023-09-29). "Schott Pharma geht mit Freshfields an die Frankfurter Börse" [Schott Pharma goes to the Frankfurt Stock Exchange with Freshfields]. Extrajournal.Net (in German). Retrieved 2024-06-24.
  13. ^ "Schott Pharma prices IPO at 27 euros per share". Reuters. 2023-09-27. Retrieved 2024-06-24.
  14. ^ Jump up to: a b "SCHOTT Pharma feiert erfolgreiches Börsendebüt: Erstkurs über Ausgabepreis" [SCHOTT Pharma celebrates successful stock market debut: First price on issue price]. Finanzen Net (in German). 2023-09-28. Retrieved 2024-06-24.
  15. ^ Farr, Emma-Victoria; Mayo Cerqueiro, Pablo (2023-09-28). "Schott Pharma shares jump 16% in Frankfurt trading debut". reuters.com. Reuters. Retrieved 2024-02-28.
  16. ^ Jump up to: a b "Schott Pharma startet erfolgreich an der Börse". tagesschau.de. 2023-09-28. Retrieved 2024-02-28.
  17. ^ Ingerl, Christian (2023-12-13). "Profitabler Small Cap: Zulieferer Schott Pharma bald im SDax". Capital. Retrieved 2024-02-28.
  18. ^ "Größter Börsengang in 2023: So hat sich die SCHOTT Pharma-Aktie seit ihrem IPO entwickelt - und so könnte es in 2024 nun weitergehen". finanzen.net. 2024-01-24. Retrieved 2024-02-28.
  19. ^ Jump up to: a b Zeitung, Badische (2022-12-02). "SCHOTT Pharma: Ein globales Kompetenzzentrum in Müllheim". Badische Zeitung (in German). Retrieved 2024-06-24.
  20. ^ Schlegel, Marion (2023-12-19). "SDAX-Neuling Schott Pharma gibt ordentlich Gas: Zahlen kommen gut an". www.deraktionaer.de (in German). Retrieved 2024-06-24.
  21. ^ Jump up to: a b c "SCHOTT Pharma baut Produktion in China und Ungarn aus – ZWP online – das Nachrichtenportal für die Dentalbranche". www.zwp-online.info (in German). 2022-09-22. Retrieved 2024-06-24.
  22. ^ Jump up to: a b "SCHOTT: solides Ergebnis trotz konjunktureller Herausforderungen – ZWP online – das Nachrichtenportal für die Dentalbranche" [SCHOTT: solid result despite economic challenges]. www.zwp-online.info (in German). 2024-02-12. Retrieved 2024-06-24.
  23. ^ SCHOTT Pharma Annual Report 2022/2023, SCHOTT Pharma, p. 14, retrieved 2024-02-28
  24. ^ Kaiser, Lea (2023-10-24). "Next generation pharma glass: SCHOTT AG launches FIOLAX® Pro Glass tubing". BusinessWire. Retrieved 2024-06-24.
  25. ^ "Schott Pharma rolls out pre-filled polymer syringes for deep-cold medication". NS Medical Devices. 2023-05-18. Retrieved 2024-02-28.
  26. ^ Kolf, Ingo (2024-05-15). "Kurs bricht ein: Schott Pharma: Trübe Aussichten führen zu drastischem Kurseinbruch". FinanzNachrichten.de (in German). Retrieved 2024-06-24.
  27. ^ Mills, Jess (2023-05-02). "Schott appoints Supervisory Board of Schott Pharma". Glass International. Retrieved 2024-06-24.
  28. ^ "SCHOTT bestellt Aufsichtsrat der SCHOTT Pharma AG" [SCHOTT appoints Supervisory Board of SCHOTT Pharma AG]. ZWP-online. 2023-05-02. Retrieved 2024-06-24.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Schott_Pharma&oldid=1232298642"
Arc.Ask3.Ru: конец переведенного документа.
Arc.Ask3.Ru
Номер скриншота №: f20272a927c389739701600f60df3362__1719958320
URL1:https://arc.ask3.ru/arc/aa/f2/62/f20272a927c389739701600f60df3362.html
Заголовок, (Title) документа по адресу, URL1:
Schott Pharma - Wikipedia
Данный printscreen веб страницы (снимок веб страницы, скриншот веб страницы), визуально-программная копия документа расположенного по адресу URL1 и сохраненная в файл, имеет: квалифицированную, усовершенствованную (подтверждены: метки времени, валидность сертификата), открепленную ЭЦП (приложена к данному файлу), что может быть использовано для подтверждения содержания и факта существования документа в этот момент времени. Права на данный скриншот принадлежат администрации Ask3.ru, использование в качестве доказательства только с письменного разрешения правообладателя скриншота. Администрация Ask3.ru не несет ответственности за информацию размещенную на данном скриншоте. Права на прочие зарегистрированные элементы любого права, изображенные на снимках принадлежат их владельцам. Качество перевода предоставляется как есть. Любые претензии, иски не могут быть предъявлены. Если вы не согласны с любым пунктом перечисленным выше, вы не можете использовать данный сайт и информация размещенную на нем (сайте/странице), немедленно покиньте данный сайт. В случае нарушения любого пункта перечисленного выше, штраф 55! (Пятьдесят пять факториал, Денежную единицу (имеющую самостоятельную стоимость) можете выбрать самостоятельно, выплаичвается товарами в течение 7 дней с момента нарушения.)